Longevity Lab Report
← All supplements

Semax

A Russian nootropic peptide riding a policy wave: the human evidence never left home.

D+

Evidence grade

D

Worth it

$40-80/month

Typical cost

DoseNo established dose exists for any use this library grades. Russian clinical products are 0.1 percent or 1 percent intranasal solutions dosed in drops; online nootropic practice copies those patterns without a studied regimen behind them for healthy users.

BasisThe human literature consists of small Russian studies, largely in stroke and optic-nerve patients, mostly uncontrolled or reported without the methods detail Western review requires, plus healthy-volunteer experiments from the same institutes.

Semax is a synthetic heptapeptide modelled on a fragment of ACTH (the melanocortin 4-7 sequence with a stabilizing tail), developed in Russia and used there intranasally for stroke recovery and cognitive complaints. We grade Semax D+ on evidence and D for worth-it at about $40-80 per month.

What it does

Semax is a synthetic heptapeptide modelled on a fragment of ACTH (the melanocortin 4-7 sequence with a stabilizing tail), developed in Russia and used there intranasally for stroke recovery and cognitive complaints. It is sold online as a nootropic nasal spray. It has no approval from the FDA or any Western regulator, and its clinical literature is overwhelmingly Russian, small, and decades deep in a research tradition Western reviewers have not replicated.

What the research says

  • Improves focus, cognition, or mental performance in healthy people

    Evidence: weak. No controlled human trial supports it. The claim travels on mechanism (melanocortin and neurotrophin signalling in animal work) and community testimonials from the nootropic market that the current policy wave has amplified.

  • Aids recovery after stroke

    Evidence: weak. Russian clinical use and small studies report benefit; the trials are old, small, and not independently replicated, and stroke care is prescription medicine in any case. Recorded for completeness of the compound's history, not as a use this library can support.

The human literature consists of small Russian studies, largely in stroke and optic-nerve patients, mostly uncontrolled or reported without the methods detail Western review requires, plus healthy-volunteer experiments from the same institutes. No randomized trial of semax for cognition, focus, or any longevity claim exists in the indexed Western literature, no regulator outside its home system has approved it, and the nootropic use driving current demand has no controlled human data behind it at all. The plus over a flat D reflects that a real, if weak and unreplicated, clinical literature exists in its home system, which separates it from compounds with none.

Is it worth it?

DWorth it

At research-chemical prices for an unregulated imported spray, the buyer pays a premium for the least-verified claim set in the peptide family: no controlled human data for the use being bought, no product verification, and no regulator anywhere in the chain. Derived from the October 2026 worth-it model.

Typical cost

$40-80/month

Common form, not a brand recommendation

Dosage context emerging

No established dose exists for any use this library grades. Russian clinical products are 0.1 percent or 1 percent intranasal solutions dosed in drops; online nootropic practice copies those patterns without a studied regimen behind them for healthy users.

The worth-it ranking

Semax sits outside the worth-it ranking of 38.

Semax sits outside that ranking of 38. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.

  1. 1AWorth itCreatine evidence A-~$5-10/mo
  2. 2AWorth itCaffeine evidence B+~$5-10/mo
  3. 3AWorth itVitamin D evidence B~$5-8/mo

See the full ranking of 38 →

When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.

Safety notes

Human safety data are as thin as the efficacy data: the Russian literature reports good tolerability, and there is no Western pharmacovigilance base, no established interaction profile, and no long-term follow-up literature. Online products are unregulated research chemicals or imported sprays with unverified contents. As a research peptide it is never suggested by our stack builder at any level. Talk to your doctor. This page is information, not medical advice.

Changelog

Last updated 2026-11-04

  • 2026-11-04|Initial grading: semax graded on its expedited slot (queue decision 2026-11-03) as the HHS policy wave drove demand against no live record. Evidence D+: a real but small, old, and unreplicated Russian clinical literature, no controlled human trial for the nootropic use driving demand, and no Western approval. Goals are empty by design: no benefit in the record reaches the strength a library goal requires.

The week's longevity and biohacking news.

Every story graded against the evidence. Free. Unsubscribe anytime.

The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.

Every grade follows a published rubric. Sponsors do not influence findings or grades.